Entrada Therapeutics (TRDA) 10% Owner Sells 259,837 Shares

What Happened
MPM BioVentures 2018, L.P. (reported as a 10% owner and part of affiliated MPM BioVentures funds) sold a total of 259,837 shares of Entrada Therapeutics (TRDA) in open‑market transactions on Sept 4, Sept 8 and Sept 9, 2026. The individual trades were: 38,500 shares at $7.11 on Sept 4 ($273,735), 192,500 shares at $7.41 on Sept 8 ($1,426,425), and 28,837 shares at $7.13 on Sept 9 ($205,608). Combined proceeds were about $1.91 million. These were sales (S), not purchases or option exercises.

Key Details

• Transaction dates & prices: Sept 4 — 38,500 @ $7.11; Sept 8 — 192,500 @ $7.41; Sept 9 — 28,837 @ $7.13.
• Total sold: 259,837 shares for ~$1,905,768.
• Shares held after transactions (affiliated holdings per filing footnote): combined ~3,885,115 shares across MPM-affiliated vehicles (e.g., BV2018 ~1,810,592; BV2014 ~1,764,167; plus related vehicles). See footnote F10 for the full breakdown.
• Footnotes: sales were allocated among several affiliated MPM funds (BV 2014, BV 2018 and related B/AM entities — see F1/F5/F8); weighted‑average and per‑trade price ranges are noted in the filing (details available on request per the form).
• Beneficial ownership: reporting persons disclaim beneficial ownership except to the extent of pecuniary interest (see F4).
• Filing: Form 4 was filed Sept 9, 2026 and covers trades dated Sept 4–9; no late‑filing flag indicated in the filing.

Context
This is institutional selling by a reported 10% holder and not an individual company executive. Sales by large holders can reflect portfolio rebalancing or liquidity needs and are not, by themselves, proof of a change in company outlook. Purchases generally carry more direct interpretive weight for retail investors than routine institutional sales.